Monica Holmber, PharmD, BCPS
Advertisement
Articles by Monica Holmber, PharmD, BCPS
Combination therapy with both nivolumab and relatlimab leads to increased T-cell activation compared with monotherapy with either agent alone.
The FDA approved an expanded indication for Isentress (raltegravir) to include the treatment of HIV-1 infection in children 2 years and older.
Advertisement
Latest Updated Articles
- New FDA Actions: Merck & Co Inc's Isentress
August 16th 2012
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5